Comment: Management of De Novo Chronic Myelogenous Leukemia and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation Tyrosine Kinase Inhibitor Dasatinib için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Comment: Management of De Novo Chronic Myelogenous Leukemia and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation Tyrosine Kinase Inhibitor Dasatinib | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Ağustos 2025 | 0 |
| Eylül 2025 | 0 |
| Ekim 2025 | 0 |
| Kasım 2025 | 0 |
| Aralık 2025 | 0 |
| Ocak 2026 | 0 |
| Şubat 2026 | 0 |
